Diuretic Use in Hemodialysis Patients With Residual Renal Function

End Stage Renal Disease on Dialysis Clinical Trial

— DIURESED  

Official title:

Diuretic Use in Hemodialysis Patients With Residual Renal Function: a Proof of Concept Study

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05915286
• Other study ID #: Pro00119451
• Status: Suspended
• Phase: Phase 4
• Start date: May 29, 2023
• Est. completion date: February 1, 2025

Study information

• Verified date: March 2024
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot trial will evaluate the use of diuretic medications (furosemide and chlorthalidone) in participants on dialysis to see if these medications work to preserve existing kidney function, increase urine output, and reduce weight gain between dialysis treatments. Diuretics, which are sometimes called water pills, help the body to get rid of salt (sodium) and water. There are currently no guidelines for the use of diuretic medications in dialysis patients, including the type to use, or how much to use.

Description:

Fluid overload, or extracellular fluid volume expansion, in patients on hemodialysis is an important predictor of mortality. It is associated with hypertension and left ventricular hypertrophy - both risk factors for cardiovascular disease. In the United States, 80% of patients receiving hemodialysis have hypertension and 40% of patients on hemodialysis die from cardiovascular disease. The pathophysiology of hypertension in these patients is multifactorial, however, combined excess fluid and sodium is a key contributor. While ultrafiltration (removal of fluid through dialysis) is important in managing fluid overload, fluid removed by hemodialysis is a non-physiological process which imposes hemodynamic stress on the cardiovascular system in uremic patients. This system is already maladaptive as a result of decreased baroreceptor sensitivity and increased vascular stiffness, leading to higher risk of hemodynamic instability when fluid is removed from the intravascular compartment. In patients who are anuric, restriction of fluid and sodium intake and ultrafiltration are the only options for volume control. In patients who continue to produce urine, however, optimizing the amount of urine produced could improve fluid overload and decrease cardiovascular stress. Previous studies have shown that patients on hemodialysis who have residual renal function have better volume and sodium control. Higher residual renal function and higher urine output lead to a lower interdialytic weight gain in patients receiving hemodialysis; each of these factors have been associated with lower mortality. One intervention that may increase or help maintain residual renal function and increase urine output and therefore reduce interdialytic weight gain is diuretic therapy, which promotes the excretion of sodium and water by the native kidneys. Questions remain regarding the dose-response of the drug furosemide, about the utility of adding the drug chlorthalidone, and their clinical affects. The main objective of this study is to determine the effects of starting, and escalating doses of diuretic medications (furosemide +/- chlorthalidone) on 24-hour urine output (volume) over a five-week period in patients on hemodialysis who produce >200cc per day of urine. Secondary objectives are: 1. To evaluate the effect of diuretic medications on residual renal function 2. To evaluate the effect of different doses of diuretics on interdialytic weight gain, ultrafiltration rates and intradialytic hypotension 3. To examine the effect of diuretics on patient reported outcomes 4. To evaluate adverse effects of different doses of diuretics 5. To measure serum furosemide levels in this patient population

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 34
• Est. completion date: February 1, 2025
• Est. primary completion date: February 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (age 18 years or older), who are within their first 12 months of chronic (expected to need dialysis for at least 6 months), in-centre hemodialysis therapy, and
• Residual renal function defined as 24-hour urine volume >200cc, and
• Life expectancy of at least 6 months, and
• Participants must be able to understand the consent process and be able to sign a consent form or have a substitute decision maker who is able to understand and sign consent on their behalf. In the case of non-English speaking participants, a translator service will be used to provide study information and obtain consent.

Exclusion Criteria:

• Unable to complete baseline urine collection
• Documented allergy or adverse reaction to furosemide or chlorthalidone.
• Unable to take oral medications
• Patients expecting to change modality (peritoneal dialysis, home dialysis) or to receive a renal transplant in the next 6 weeks
• History of hypokalemia (<3.0 mmol/L), hypomagnesemia (<0.6mmol/L), or hypocalcaemia (<1.9mmol/L) in preceding 2 weeks.
• Already participating in another study and one of the studies could interfere with the other study
• Use of loop, or thiazide diuretic medications in the last week (if a patient is on chronic diuretics, they would need to be discontinued for 1 week before starting the trial)

Related Conditions & MeSH terms

• End Stage Renal Disease on Dialysis
• Kidney Failure, Chronic

Intervention

Drug:
• Furosemide
Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
• Chlorthalidone
Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 1
Primary	Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 2
Primary	Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 3
Primary	Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 4
Primary	Change in 24-hour urine output	Change in urine output measured from 24-hour urine collection.	Week 5
Primary	Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 1
Primary	Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 2
Primary	Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 3
Primary	Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 4
Primary	Change in residual renal function	Calculated based on weekly bloodwork (urea and creatinine levels) and 24-hour urine collection.	Week 5
Secondary	Interdialytic weight gain	Patient weight measured in kilograms	Week 1
Secondary	Interdialytic weight gain	Patient weight measured in kilograms	Week 2
Secondary	Interdialytic weight gain	Patient weight measured in kilograms	Week 3
Secondary	Interdialytic weight gain	Patient weight measured in kilograms	Week 4
Secondary	Interdialytic weight gain	Patient weight measured in kilograms	Week 5
Secondary	Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 1
Secondary	Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 2
Secondary	Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 3
Secondary	Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 4
Secondary	Patient-reported outcomes - ESAS-r	Patient reported outcomes using the Edmonton Symptom Assessment System-revised (ESAS-r) questionnaire.	Week 5
Secondary	Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 1
Secondary	Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 2
Secondary	Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 3
Secondary	Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 4
Secondary	Patient-reported outcomes - Muscle cramps	Patient reported outcomes using a muscle cramps question.	Week 5
Secondary	Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 1
Secondary	Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 2
Secondary	Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 3
Secondary	Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 4
Secondary	Adverse effects	Adverse effects based on symptoms and weekly bloodwork.	Week 5
Secondary	Urine furosemide levels	Urine furosemide levels from weekly urine samples	Week 3
Secondary	Urine furosemide levels	Urine furosemide levels from weekly urine samples	Week 4
Secondary	Urine furosemide levels	Urine furosemide levels from weekly urine samples	Week 5